8-K
filed March 12, 2024, 7:59 PM ET
ticker ENTA
CIK 0001177648
other material
confidence high
sentiment neutral
materiality 0.50
Enanta shareholders approve 975,000-share increase to 2019 Equity Incentive Plan
ENANTA PHARMACEUTICALS INC
- Stockholders approved amendment to 2019 Equity Incentive Plan, increasing share reserve by 975,000 shares.
- Re-elected Class II directors Yujiro S. Hata, Kristine Peterson, and Terry C. Vance.
- Advisory say-on-pay vote passed with 12,306,697 votes for (79.4% of votes cast).
- Ratified PricewaterhouseCoopers LLP as independent auditor for FY2024.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ENANTA PHARMACEUTICALS INC shareholders approved Approve an Amendment to Our 2019 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder by 975,000 shares at the 2024-03-06 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2024-03-06
Exact text from the filing
Proposal No. 2: To Approve an Amendment to Our 2019 Equity Incentive Plan. The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 975,000 shares. Votes For Votes Against Abstain Broker Non-Votes 8,076,566 7,421,300 21,356 1,156,034
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ENANTA PHARMACEUTICALS INC shareholders approved Advisory vote on executive compensation (say-on-pay) at the 2024-03-06 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2024-03-06
Exact text from the filing
Proposal No. 3: To Approve, on an Advisory Basis, the Compensation Paid to the Company’s Named Executive Officers. The stockholders approved the advisory vote on executive compensation, referred to as a “say-on-pay” vote. Votes For Votes Against Abstain Broker Non-Votes 12,306,697 3,196,342 16,183 1,156,034
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ENANTA PHARMACEUTICALS INC shareholders approved Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta’s Independent Registered Public Accounting Firm for the 2024 Fiscal Year at the 2024-03-06 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-03-06
Exact text from the filing
Proposal No. 4: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta’s Independent Registered Public Accounting Firm for the 2024 Fiscal Year. The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2024. Votes For Votes Against Abstain Broker Non-Votes 14,571,800 27,373 2,076,083 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ENANTA PHARMACEUTICALS INC shareholders approved Election of Three Class II Directors at the 2024-03-06 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-03-06
Exact text from the filing
Proposal No. 1: To Elect Three Class II Directors to Serve until the 2027 Annual Meeting or until their respective successors are elected and qualified. The stockholders re-elected the following individuals as Class II directors of the Company: Name of Director Nominee Votes For Votes Withheld Broker Non-Votes Yujiro S. Hata 13,127,063 2,392,002 1,156,191 Kristine Peterson 12,994,324 2,524,741 1,156,191 Terry C. Vance 12,169,732 3,209,519 1,296,005
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.